Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CX-801 |
| Synonyms | |
| Therapy Description |
CX-801 is a masked form of the cytokine IFNalpha2b that is unmasked by proteases in the tumor microenvironment, which potentially enhances antitumor immune response and decreases tumor cell proliferation (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CX-801 | CX 801|CX801 | CX-801 is a masked form of the cytokine IFNalpha2b that is unmasked by proteases in the tumor microenvironment, which potentially enhances antitumor immune response and decreases tumor cell proliferation (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06462794 | Phase I | CX-801 CX-801 + Pembrolizumab | First In Human Study of CX-801 in Advanced Solid Tumors | Recruiting | USA | 0 |